Jointly conducted by IRD and INSERM, this research proposes a shorter and potentially more effective tuberculosis treatment.
Daniel Atwine, researcher at TransVIHMI (Institut de Recherche pour le Développement).
Thesis defended in 2017 at the doctoral school École doctorale Sciences Chimiques et Biologiques pour la Santé (Montpellier ; 1992-....).
This research is the result of an international co-supervision between several partner institutions.
Referenced in the ABES/STAR network, this thesis meets the rigorous criteria of French higher education.
Tuberculosis remains a public health scourge, particularly in Africa, where it continues to pose a major challenge for health systems. According to the World Health Organization (WHO), sub-Saharan Africa is the most affected region, with millions of new cases each year. The standard six-month treatment, while effective, is not only lengthy but also leads to adherence issues among patients. This situation fosters the emergence of resistant strains, making the fight against this disease even more complex and costly.
Research conducted by Daniel Atwine, in collaboration with IRD (Institute for Research and Development) and INSERM (National Institute for Health and Medical Research), explores a promising alternative: increasing the dosage of rifampicin to reduce the treatment duration to three or four months. This approach could revolutionize tuberculosis management, especially in contexts where access to care is limited.
This study is set against a backdrop where new therapies are scarce and existing treatments show their limitations. By increasing the dose of rifampicin beyond the recommended 10 mg/kg, researchers observed encouraging results during clinical trials. Preliminary results show no significant increase in hepatic toxicity, a crucial point for patient safety. This is particularly important in countries like Benin, where medical resources are limited and monitoring side effects can be challenging.
The culture conversion rates at two months were also higher with solid media, suggesting increased treatment efficacy. These results are particularly significant as they indicate that patients could be cured more quickly, which is essential for reducing disease transmission in communities. Furthermore, efavirenz concentrations, an antiretroviral used to treat HIV, remained within the therapeutic range, even with high doses of rifampicin. This paves the way for combined treatments for patients co-infected with HIV and tuberculosis, a common situation in West Africa where both diseases often coexist.
However, the decrease in virological efficacy at 24 weeks in the high-dose rifampicin group raises crucial questions. How can we ensure that increasing the dose does not compromise long-term efficacy? This question is even more relevant in the African context, where health systems are often already under pressure. The results of this research need to be further explored with larger trials to confirm these observations. It is essential to conduct additional studies that take into account the genetic diversity of tuberculosis strains and variations in patient responses.
It is imperative that policymakers consider these results. Reducing the treatment duration could transform tuberculosis management, improve patient adherence, and reduce healthcare costs. The economic implications are significant, as a shorter treatment could also lessen the burden on already fragile health systems. Indeed, studies have shown that each additional month of treatment incurs extra costs for health systems, both in terms of medications and medical follow-up.
In summary, this research opens interesting prospects for the fight against tuberculosis. The results must be closely monitored and integrated into public health policies to maximize their impact. It is crucial that governments and international organizations collaborate to implement these new treatment strategies. In parallel, it is necessary to strengthen health infrastructures to ensure that patients have access to these improved treatments.
The fight against tuberculosis requires a multidimensional approach, including raising public awareness, strengthening the capacities of healthcare professionals, and improving surveillance systems. By integrating this new research into a comprehensive strategy, we could hope for a future where tuberculosis is no longer a threat to public health in Africa.
Key Facts
- 300 : Number of patients included in the RIFATOX clinical trial to evaluate the safety of high-dose rifampicin.
Access the full study
Sources and Access
Daniel Atwine. Improving TB management and control through innovative shorter anti-tuberculosis regimens. Human health and pathology. Université Montpellier, 2017. English. ⟨NNT : 2017MONTT041⟩. ⟨tel-01690745⟩